In clinical trials, the drug was shown to almost double the median survival time for patients with pancreatic cancer.

Researchers report progress in looking for signs of lung cancer in the blood.

Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug ...

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...

The TROP2-directed antibody-drug conjugate demonstrated superior efficacy over physician’s choice of chemotherapy in patients previously treated with platinum-based therapy and immunotherapy.

Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But ...

May 18 (Reuters) - Merck said on Monday its experimental drug helped certain patients with uterine cancer live longer and ...

Partnering with University of Michigan Health represents an important step in bringing Unfold AI to leading cancer centers ...

Pancreatic cancer is notoriously lethal. But new treatments mean that may be changing, and people with the disease now have ...

If this was my house and I wasn’t remediating this, you better believe the government would come in and take my property,' ...